Blog

Company News

Industry Trends

Laws Regulations

All Categories >

02

2023-02

You can’t have it all: being a CXO and developing innovative drugs.

China’s previous wave of innovative-drug enthusiasm reached a milestone with the approval and launch of several large-molecule biosimilars, only to cool off rapidly thereafter once these products were included in the national medical insurance scheme. The interim outcome of that boom was the listing of roughly 20 innovative-drug companies on the Hong Kong stock exchange, nearly all of which had PD-1 candidates in their pipelines. In this highly “me-too” market, regardless of whether a product is covered by insurance, as long as it delivers some clinical benefit, price becomes the sole metric for valuation. Among the rising stars—Xinda, Junshi Biosciences, and BeiGene—as well as the established player Hengrui Medicine, all core PD-1 products have since been added to the national reimbursement list. Yet in 2021, the combined sales of these four companies’ PD-1 products—about RMB 9 billion—still amounted to little more than a fraction of Merck’s PD-1 blockbuster Keytruda, which generated US$17.1 billion in revenue. Despite this, the aggregate market capitalization of these firms at one point surpassed Merck’s, clearly signaling a bubble.

2023-02-02

He Yousheng

06

2023-01

Holiday Notice for the Spring Festival at Hycells Biotechnology!

2023-01-06

He Yousheng

21

2022-12

Ding! Please sign for your Christmas Eve gift!

With the adjustment of epidemic prevention and control measures, Shanghai has entered a new phase in its fight against the virus. On this invisible battlefield, each of us—striving to live well and working diligently—is a warrior. We are deeply grateful to every colleague who remains steadfast at their post or stays home, tirelessly battling the virus while continuing to do their job. You are all truly outstanding.

2022-12-21

He Yousheng

21

2022-12

Hycells Bio | Dedicated to Research on Cell and Animal Models for Drug Development

Shanghai Hycells Biotechnology Co., Ltd. has long been deeply engaged in the cell and gene therapy segment of large-molecule drug development. Since its inception, the company has leveraged a solid customer base and years of accumulated R&D service expertise to establish robust technological barriers, delivering highly satisfactory services that have earned a strong reputation among new-drug R&D enterprises. As a result, it has forged long-term, stable partnerships with numerous leading CROs, cell therapy companies, and gene therapy firms. Moving forward, we will continue to optimize our clinical, technical, and business management systems as well as our service processes, thereby providing collaborative partners in the biopharmaceutical sector with services that meet even higher standards.

2022-12-21

He Yousheng

19

2022-12

To Our Original Aspiration, Embarking on a New Journey | Hycells Biological Relocates to New Headquarters

2022 was an extraordinary year for everyone. Although the pandemic restricted our movements, it only intensified our collective commitment to safeguarding human life and health. In November 2022, Hycells Biotechnology turned a new, milestone chapter in its history by relocating to a brand-new facility—marking a significant leap forward in the company’s manufacturing and R&D capabilities and providing a powerful boost to its sustained growth. Thanks to the concerted efforts of colleagues across all departments, we officially moved into our new premises on November 21, 2022.

2022-12-19

He Yousheng

21

2022-05

Detailed Implementation Rules for the Regulations on the Administration of Human Genetic Resources (Draft for Comments)

2022-05-21

He Yousheng
< 1...20212223 >